Spots Global Cancer Trial Database for allogeneic hematopoietic stem cell transplantation

Every month we try and update this database with for allogeneic hematopoietic stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome	NCT05413356	Bronchiolitis O... Hematologic Mal...	Ruxolitinib	18 Years - 65 Years	First Affiliated Hospital of Zhejiang University
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma	NCT00907036	Lymphoma	alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema...	16 Years - 65 Years	National Cancer Institute (NCI)
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	NCT01823198	Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related...	Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological...	7 Years - 65 Years	M.D. Anderson Cancer Center
Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL	NCT05379569	Acute B Lymphob... Allogeneic Hema...	Fludarabine	18 Years - 55 Years	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis	NCT03118492	Secondary Myelo...	Allogeneic Hema... Cyclophosphamid... Fludarabine Glycosylated Re... Laboratory Biom... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra...	18 Years - 65 Years	City of Hope Medical Center
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant	NCT06059391	Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym...	Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil...	18 Years -	City of Hope Medical Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity	NCT03032783	Hematopoietic a...	Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Allogeneic Hema...	18 Years -	Thomas Jefferson University
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma	NCT02724904	Lymphoma	Allogeneic stem... Fludarabine Thiotepa Methotrexate	18 Years -	Massachusetts General Hospital
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	NCT04177004	Allogeneic Hema... Hematopoietic a...	Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus	12 Years -	City of Hope Medical Center
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies	NCT03272633	Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat...	Allogeneic Hema... Irradiated Allo...	18 Years -	Rutgers, The State University of New Jersey
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor	NCT01598025	Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly...	total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom...	- 19 Years	Memorial Sloan Kettering Cancer Center
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma	NCT02504359	Plasma Cell Leu... Recurrent Plasm...	Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus	18 Years - 65 Years	OHSU Knight Cancer Institute
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML	NCT01191957	Acute Myeloid L...	Busulphan plus ... Busulphan plus ...	40 Years - 65 Years	Gruppo Italiano Trapianto di Midollo Osseo
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT	NCT02670252	Allogeneic Hema... Busulfan Total Body Irra... Acute Lymphocyt...	Busulfan (BU) Cyclophosphamid... Total Body Irra...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	NCT02101853	Recurrent B Acu...	Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	NCT01341301	Hematologic Mal...	Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom...	18 Years -	Thomas Jefferson University
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Phase II Trial of Pentostatin and Targeted Busulfan	NCT00496340	Hematologic Mal...	Pentostatin Busulfan Rituximab Allogeneic Hema...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission	NCT00005940	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom...	16 Years - 55 Years	Fred Hutchinson Cancer Center
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome	NCT05674539	Acute Myeloid L... Myelodysplastic... Allogeneic Hema...	Fludarabine and... Fludarabine and...	18 Years -	Wuhan Union Hospital, China
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia	NCT03900949	Acute Myeloid L...	Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin	18 Years -	Ohio State University Comprehensive Cancer Center
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL	NCT03564704	Leukemia Leukemia, Acute Adult Lymphobla... Leukemia, Lymph... Leukemia, T Cel... Adult Acute Lym... Lymphoblastic L... Lymphoblastic L...	Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping Chidamide PET-CT scan	14 Years - 55 Years	Nanfang Hospital, Southern Medical University
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00039377	Adult Acute Lym...	imatinib mesyla... methotrexate vincristine sul... leucovorin calc... peripheral bloo... autologous hema... allogeneic hema... total-body irra... tacrolimus filgrastim etoposide cyclophosphamid... cytarabine laboratory biom...	15 Years - 59 Years	National Cancer Institute (NCI)
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia	NCT01824693	Juvenile Myelom...	Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus	3 Months - 18 Years	Children's Oncology Group
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab	NCT06125106	Acute Lymphobla...	Blinatumomab	18 Years - 70 Years	Zhejiang University
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia	NCT03900949	Acute Myeloid L...	Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin	18 Years -	Ohio State University Comprehensive Cancer Center
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01503242	Plasma Cell Mye... Refractory Plas...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Total-Body Irra... Yttrium Y 90 An...	18 Years - 65 Years	Fred Hutchinson Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)	NCT02441803	Leukemia	Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin	18 Years - 60 Years	M.D. Anderson Cancer Center
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant	NCT01244906	Hematologic Neo...	Allogeneic Hema...	18 Years - 75 Years	Northside Hospital, Inc.
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia	NCT00550992	Leukemia	anti-thymocyte ... asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide leucovorin calc... melphalan mercaptopurine methotrexate mitoxantrone hy... pegaspargase prednisolone prednisone therapeutic hyd... thioguanine vincristine sul... allogeneic bone... allogeneic hema... umbilical cord ...	- 1 Year	Dutch Childhood Oncology Group
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT01256398	Acute Lymphobla... Adult B Acute L...	Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul...	18 Years -	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	NCT01700946	Recurrent B-Cel... Recurrent Child...	dexamethasone vincristine sul... rituximab clofarabine cyclophosphamid... etoposide aldesleukin pegaspargase methotrexate mercaptopurine cytarabine mitoxantrone teniposide vinblastine natural killer ... laboratory biom... therapeutic hyd... allogeneic hema... CliniMACS	- 21 Years	St. Jude Children's Research Hospital
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation	NCT04464889	Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph...	MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal...	18 Years -	Medigene AG
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma	NCT01208896	Lymphoma, Folli... Stem Cell Trans...	Reduced_intensi...	18 Years - 65 Years	University Hospital, Bordeaux
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	NCT04579523	Plasma Cell Mye... Recurrent Plasm... Refractory Plas...	Allogeneic Hema... Astatine At 211... Cyclophosphamid... Fludarabine Pho... Total-Body Irra...	18 Years - 70 Years	Fred Hutchinson Cancer Center
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies	NCT03712878	Hematopoietic a...	Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Allogeneic Hema... Tacrolimus Mycophenolate M...	18 Years -	Thomas Jefferson University
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation	NCT06028828	Allogeneic Hema... Allogeneic Stem... Hematologic Mal...	Fludarabine Melphalan Total Body Irra...	18 Years - 70 Years	University of California, Irvine
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission	NCT00005940	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom...	16 Years - 55 Years	Fred Hutchinson Cancer Center
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants	NCT03624530	Philadelphia Ch... Tyrosine Kinase... Minimal Residua... Allogeneic Hema...	Tyrosine kinase...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant	NCT03057054	Hematopoietic a... Leukemia Lymphoma	Allogeneic Hema... Lactobacillus p... Lactobacillus p... Placebo Adminis...	2 Years - 25 Years	Children's Oncology Group
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT	NCT04098653	Allogeneic Hema... Conditioning Myeloid Tumors	Decitabine Busulfan (BU) Cyclophosphamid...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT	NCT04098653	Allogeneic Hema... Conditioning Myeloid Tumors	Decitabine Busulfan (BU) Cyclophosphamid...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01252667	Acute Myeloid L...	Allogeneic Hema... Clofarabine Cyclosporine Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra...	2 Years -	Fred Hutchinson Cancer Center
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma	NCT02652468	Lymphoma	Fludarabine Pho... Mesna Cyclophosphamid... Total nodal irr... T Cell-Depleted... Allogeneic Hema... Peripheral Bloo... Mycophenolate M... Tacrolimus Rituximab	18 Years - 75 Years	University of Wisconsin, Madison
MRD Response-adapted Allo-HSCT for Adverse-risk AML	NCT06301425	Acute Myeloid L...	Intervention gr... Control group	16 Years - 65 Years	Peking University People's Hospital
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT00454480	Leukemia Myelodysplastic...	alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ...	-	National Cancer Institute (NCI)
A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score	NCT06279338	Myelodysplastic...	Azacitidine Inj...	18 Years -	Wuhan Union Hospital, China
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation	NCT01596257	Leukemia	allogeneic hema... CliniMACS	- 75 Years	Memorial Sloan Kettering Cancer Center
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	NCT01168219	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... de Novo Myelody... Myelodysplastic... Myelodysplastic... Recurrent Adult... Secondary Myelo...	Allogeneic Hema... Anti-Thymocyte ... Azacitidine Busulfan Fludarabine Pho... Laboratory Biom... Methotrexate Pharmacological... Tacrolimus	18 Years - 74 Years	National Cancer Institute (NCI)
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML	NCT01191957	Acute Myeloid L...	Busulphan plus ... Busulphan plus ...	40 Years - 65 Years	Gruppo Italiano Trapianto di Midollo Osseo
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	NCT05589844	Cytomegaloviral... Hematopoietic a...	Allogeneic Hema... Biospecimen Col... CMV pp65 Peptid...	18 Years -	Roswell Park Cancer Institute
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)	NCT01379209	Graft Versus Ho...	RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus	18 Years -	Regimmune Corporation
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	NCT01858740	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil...	Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra...	- 21 Years	Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant	NCT01534143	Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi...	pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases	NCT05827835	Hematologic Dis... Neoplasms	CD7 CAR-T cells... Allogeneic hema...	18 Years - 75 Years	Zhejiang University
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	NCT00093743	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea...	fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m...	-	Fred Hutchinson Cancer Center
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT	NCT03596892	Allogeneic Hema... Conditions Mixed-lineage-l...	Decitabine Busulfan (BU) Cyclophosphamid...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Extracorporal Photopheresis Pilot Study	NCT00930566	Hematological M...	methoxsalen Extracoporal Ph...	18 Years - 65 Years	Hospices Civils de Lyon
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	NCT01008462	B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac...	Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	NCT00093743	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea...	fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m...	-	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	NCT02003222	Acute Lymphobla... B Acute Lymphob...	Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging	30 Years - 70 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: